Meprobamate-Induced Fixed Drug Eruption

ISSN: 2212-3911 (Online)
ISSN: 1574-8863 (Print)

Volume 10, 3 Issues, 2015

Download PDF Flyer

Current Drug Safety

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Dr. Seetal Dodd
University of Melbourne
Geelong, 3220

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Meprobamate-Induced Fixed Drug Eruption

Current Drug Safety, 9(2): 161-162.

Author(s): Ahmed Zaiem, Widd Kaabi, Talel Badri, Ghozlane Lakhoua, Rym Sahnoun, Sarrah Kastalli, Riadh Daghfous, Mohamed Lakhal and Sihem El Aidli.

Affiliation: National Center of Pharmacovigilance, 9 Avenue du Dr Zouhaier Essafi 1006, Tunis, Tunisia.


Meprobamate is usually a safe drug prescribed for anxiety disorders. Fixed drug eruption (FDE) is an exceptional cutaneous adverse effect of this drug. We report a case of FDE induced by meprobamate with positive patch test. A 22-year-old woman was prescribed for depression meprobamate, aceprometazine, valpromide and lorazepam. On the second day of treatment, the patient presented red erythematous and pruriginous plaques in the limbs and the face. After stopping the previous treatment, the patient's lesions resolved completely within 3 weeks with residual pigmentation. One month later, patch tests were performed and were positive to meprobamate. Exceptional cases of FDE were reported in literature with meprobamate. None has reported the use of patch test to confirm the diagnosis.


Fixed drug eruption, meprobamate, patch-test.

Download Free Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 9
Issue Number: 2
First Page: 161
Last Page: 162
Page Count: 2
DOI: 10.2174/1574886309666140121105737

Related Journals

Webmaster Contact: Copyright © 2015 Bentham Science